Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

Table 1 Included patient characteristics

		MUD/MMUD	Unrelated UCB
		N = 6(5)*	N = 8(6)*
		N	N
Sex
	Male	3 (2)	4 (2)
	Female	3	4
Age
	<10	2	6 (4)
	10–20	2	1
	21–40	1	1
	>40	1 (0)	0
Diagnosis
	ALL	2	1
	AML	0	2 (1)
	Hodgkin lymphoma	1	0
	Myelodysplastic syndrome	1	1
	Multiple myeloma	1 (0)	0
	Aplastic anemia	0	2 (1)
	Fanconi anemia	0	1
	Shwachman syndrome	1	0
	Primary immunodeficiency (HLA-II defect)	0	1
Graft
	MUD	3 (2)	0
	MMUD	3	0
	Unrelated UCB	0	8 (6)
Conditioning regimen
	Myeloablative	3	5 (4)
	Non myeloablative	3 (2)	3 (2)
T cell depletion
	ATG	6 (5)	7 (5)
GVHD prophylaxis
	Ciclosporin-A + MTX	3 (2)	0
	Ciclosporin-A + MMF	2	5 (4)
	Rapamycin + MMF	1	0
	MMF	0	1
	Ciclosporin-A + corticosteroid	0	2 (1)
GVHD status prior to ADV-VST transfer
	No GVHD	1	4 (3)
	Acute GVHD grade I-II	5 (4)	1
	Acute GVHD grade III-IV	0	3 (2)
	Chronic GVHD	2	0
ADV status
	Infection	1	2 (0)
	Disease	5 (4)	6
Antiviral treatment prior to ADV-VST transfer
	Cidofovir	4 (3)	7 (5)
	Ribavirin	0	1
	None	2	0
Day ADV-VST transfer post-HSCT (days)
	<50	0	2
	50–100	2	1
	>100	3	3
	Not infused	1	2

(M)MUD (mis-)matched unrelated donor, UCB umbilical cord blood, ALL acute lymphoblastic leukemia, AML acute myeloblastic leukemia, ATG antithymocyte globulin, MTX methotrexate, MMF mycophenolate mofetil, GVHD graft versus host disease, ADV adenovirus, VSTs virus-specific T cells
*Numbers of patients who received ADV-VST are presented in brackets

ISSN: 1756-8722